**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 84976

**Manuscript Type:** CASE REPORT

**Antithrombin III deficiency in a patient with recurrent venous thromboembolism: A case report**

Luo JQ *et al*. AT3 deficiency in a VTE patient

Jia-Qing Luo, Shuai-Shuai Mao, Jin-Yi Chen, Xue-Ying Ke, Yue-Feng Zhu, Wei Huang, Hai-Ming Sun, Zhen-Jie Liu

**Jia-Qing Luo, Hai-Ming Sun,** Department of Vascular Surgery, Changxing People's Hospital, Changxing 313100, Zhejiang Province, China

**Shuai-Shuai Mao,** Department of Endocrinology, Changxing People's Hospital, Changxing 313100, Zhejiang Province, China

**Jin-Yi Chen, Zhen-Jie Liu,** Department of Vascular Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China

**Xue-Ying Ke, Yue-Feng Zhu,** Department of Vascular Surgery, Sir Runrun Shaw Hospital of Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China

**Wei Huang,** Department of General Surgery, Changxing People's Hospital, Changxing 313100, Zhejiang Province, China

**Author contributions:** Luo JQ and Mao SS contributed to manuscript writing and editing, and data collection; Chen JY, Ke XY, and Zhu YF contributed to data collection and analysis; Huang W, Sun HM and Liu ZJ contributed to conceptualization and supervision; All authors have read and approved the final manuscript.

**Supported by** the National Natural Science Foundation of China, No. 81670433 and No. 81970398; the Project of Zhejiang Medical Young Talents (2017); Zhejiang Medical and Health Science and Technology Project, No. 2020RC014; and the Natural Science Foundation of Zhejiang Province, No. LR22H020002.

**Corresponding author: Hai-Ming Sun, MD, Chief Physician,** Department of Vascular Surgery, Changxing People's Hospital, No. 66 Taihu Middle Road, Changxing 313100, Zhejiang Province, China. sun76543212023@163.com

**Received:** April 27, 2023

**Revised:** May 19, 2023

**Accepted:** June 26, 2023

**Published online:**

**Abstract**

BACKGROUND

Antithrombin III (AT3) deficiency, an autosomal dominant disease, increases the likelihood of an individual developing venous thromboembolism (VTE). Long-term anticoagulation treatment is required for those suffering from AT3 deficiency.

CASE SUMMARY

A man aged 23, who had a history of deep venous thrombosis (DVT), experienced recurrent pain and swelling in his right lower extremity for three days following withdrawal of Rivaroxaban. He was diagnosed with DVT and antithrombin III deficiency as genetic testing revealed a single nucleotide variant in *SERPINC1* (c.667T>C, p.S223P). The patient was advised to accept long-term anticoagulant therapy.

CONCLUSION

Inherited AT3 deficiency due to *SERPINC1* mutations results in recurrent VTE. Patients may benefit from long-term anticoagulant therapy.

**Key Words:** Antithrombin; Venous thrombosis; SERPINC1; Single nucleotide variant; Anticoagulant therapy; Case report

Luo JQ, Mao SS, Chen JY, Ke XY, Zhu YF, Huang W, Sun HM, Liu ZJ. Antithrombin III deficiency resulting from a single nucleotide variant in *SERPINC1* in a patient with recurrent venous thromboembolism: A case report. *World J Clin Cases* 2023; In press

**Core Tip:** Hereditary thrombophilia can be attributed to mutations in genes such as *PROS, PROC, SERPINC1*, and *F5*. Compared to mutations in other genes, mutations of *SERPINC1* consistently lead to a more pronounced thrombophilia. Patients with this type of mutation are often advised to take warfarin as a therapeutic measure. However, evidence on the efficacy of direct oral anticoagulants is inadequate. Following identification of the *SERPINC1* mutation, our patient was advised to take Rivaroxaban for 5 years to prevent the possibility of thrombus recurrence. This report may supply proof of the efficacy of direct oral anticoagulants in individuals suffering from hereditary thrombophilia.

**INTRODUCTION**

Venous thromboembolism (VTE), consisting of pulmonary embolism (PE) and deep venous thrombosis (DVT), is a significant public health hazard. Approximately 20% of patients have unprovoked VTE. Moreover, 10%~40% of unprovoked VTE patients were diagnosed with inherited thrombophilia[1,2]. Inherited antithrombin III (AT3) deficiency is a particularly concerning form of inherited thrombophilia. AT3 belongs to the serine protease inhibitor superfamily (SERPIN). AT3 is a major inhibitor of plasma serine protease, and it works to inactivate clotting factors like thrombin, as well as factors Xa, IXa, XIa, and XIIa. Different mutations in *SERPINC1* are responsible for Inherited AT3 deficiency, a thrombotic disorder which is inherited in an autosomal dominant fashion[3]. It is estimated that between 0.02%-0.25% of the general population and 2%-5% of those with VTE have inherited AT3 deficiency[4,5]. AT3 deficiency is classified into two phenotypes based on the plasma levels of functional and antigenic AT. Type I is distinguished by a decrease in both functional and antigenic AT, whereas Type II presents with a decrease in functional AT but normal antigenic AT. Type II deficiency is categorized into three groups based on the location of the mutation: reactive site defects, heparin binding site defects, and pleiotropic defects[4]. We present a case of AT3 deficiency caused by a *SERPINC1* mutation, which was characterized by recurrent DVT.

**CASE PRESENTATION**

***Chief complaints***

A 23-year-old man complained of recurrent right lower extremity pain and swelling for three days.

***History of present illness***

Approximately six months after withdrawing Rivaroxaban, the patient experienced recurrent right lower extremity pain and swelling.

***History of past illness***

One year ago, the patient came to the hospital complaining of right lower extremity pain for a week. Laboratory examinations before treatment showed the followings: D-dimer level 5.74 μg/mL, hemoglobin level 135 g/L, hematocrit 40.3%, erythrocyte sedimentation rate 6 mm/h, platelet count 241 × 109/L, fibrinogen level 2.28 g/L, prothrombin time 15 s, active partial thromboplastin time 51.9 s, and the functional AT level AT3 50.5%. Doppler ultrasound revealed venous thrombosis in the right femoral and popliteal veins. After two weeks of initial therapy with low-molecular-weight heparin, the patient left the hospital. He took Rivaroxaban 15 mg twice daily as continuous therapy for a week, which was then changed to Rivaroxaban 10 mg twice daily. The therapy was continued for seven months. The patient then decided to stop anticoagulation therapy.

***Personal and family history***

There was no record of trauma, malignancy, or other medical issues in his personal history. His parents had no history of thrombosis (Figure 1A).

***Physical examination***

During physical examination, his vital signs were recorded as follows: body temperature 36.0 °C, blood pressure 110/50 mmHg, heart rate 76 bpm, and respiratory rate 18 breaths/min. Furthermore, the right lower limb was swollen.

***Laboratory examinations***

The patient's functional AT level was 50.5%, indicating AT3 deficiency. Since there were no tests available to measure the antigenic AT level, it is not feasible to identify the subtype of AT3 deficiency in this patient.

***Imaging examinations***

Computed tomography pulmonary angiography indicated the presence of filling defects in both lobar and partial segmental arteries. Doppler ultrasound of the deep veins in both lower extremities revealed the presence of deep vein thrombosis in the right lower extremity, as well as thrombosis in the middle and lower sections of the right external iliac vein. By computed tomography pulmonary angiography and Doppler ultrasound, the patient was diagnosed with right lower extremity DVT and PE.

**FINAL DIAGNOSIS**

The patient was diagnosed with DVT, PE and AT3 deficiency.

**TREATMENT**

During the acute thrombosis, the patient was treated with low-molecular-weight heparin 4100 AxaIU every 12 h. As he was suffering from both DVT and PE, he was recommended to insert an inferior vena filter to prevent worse PE. Upon the discharge, he was advised to receive life-long anticoagulation therapy with Rivaroxaban 20 mg daily.

**OUTCOME AND FOLLOW-UP**

Over the 5-year follow-up period, no recurrent DVT was observed in this patient.

**DISCUSSION**

Due to failure to block the coagulation cascade, AT3 deficiency results in a greater risk of recurrent thrombosis[3]. The AT gene, located on chromosome 1 in the q23.1-23.9 region of the genome, is 13.5 kb long and has six introns and seven exons[6]. In 1983, the first variation resulting in AT3 deficiency was reported, and, to our knowledge, more than 200 mutations have been reported to be related to the risk of thrombosis[7]. Furthermore, the mutation profile of the *SERPINC1* gene includes point mutations, splice site variants, small insertion/deletion mutations, and a few gross rearrangements[4]. The patient in this report had a point mutation. Moreover, the variant was known to result in AT3 deficiency. The AT3 activity in this patient was 50.5%. The decrease in AT3 activity supported the diagnosis.

AT3 deficiency is an autosomal dominant disorder. A heterozygous variant is linked to a heightened probability of venous thrombosis[7]. A heterogeneous variant was found following genome sequencing in this patient. Serine (S) changed to Proline (P) at position 223 (*c.667T>C, p.S223P*) on chromosome 1(Figure 1B and C). This variant was reported to be a missense change resulting in AT3 deficiency in 1984 and 2000[8,9]. In addition, this variant usually causes type I AT3 deficiency. The initial and recurrent VTE rates are different in type I and type II AT3 deficiency. Mitsuguro *et al*[10] discovered that individuals suffering from type I AT deficiency experienced more VTE occurrences compared to those with type II AT deficiency. Furthermore, Alhenc-Gelas *et al*[11] reported that among a large group of individuals with AT inherited deficiency, type I mutations demonstrated a greater likelihood of experiencing a first VTE, and type II deficiency had a lower risk for PE associated with DVT[11]. In this case, the patient was diagnosed with AT3 activity and a variant in the genotype. After withdrawing Rivaroxaban, he developed PE. We strongly advised the patient to take lifelong anticoagulant therapy.

Rivaroxaban is a selective factor Xa inhibitor. It is widely used in anticoagulation therapy. Many VTE patients prefer Rivaroxaban to warfarin, as it does not require monthly or weekly blood examinations. However, the guidelines did not mention the effects and security of Rivaroxaban in patients with inherited thrombophilia[12,13]. Moreover, few studies have focused on this issue. In our patient, Rivaroxaban seemed to be effective and safe during the six-month treatment. Recurrent VTE occurred quickly after the withdrawal of Rivaroxaban. Thus, Rivaroxaban may be effective in patients with AT3 deficiency. Some case reports have obtained similar outcomes[14-16].

**CONCLUSION**

When AT3 deficiency is suspected, gene detection is recommended. AT3-deficient patients with *SERPINC1* mutations can be recognized by genetic testing. The discovered mutation in *SERPINC1* (*c.667T>C, p.S223P*) seems to have clinical relevance in AT3 deficiency. Consequently, our patient was advised to modify his lifestyle and start on prolonged prophylactic treatment.

**REFERENCES**

1 **Mateo J**, Oliver A, Borrell M, Sala N, Fontcuberta J. Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia (EMET study). *Blood Coagul Fibrinolysis* 1998; **9**: 71-78 [PMID: 9607121 DOI: 10.1097/00001721-199801000-00009]

2 **Mateo J**, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). *Thromb Haemost* 1997; **77**: 444-451 [PMID: 9065991 DOI: 10.1055/s-0038-1655986]

3 **Corral J**, de la Morena-Barrio ME, Vicente V. The genetics of antithrombin. *Thromb Res* 2018; **169**: 23-29 [PMID: 30005274 DOI: 10.1016/j.thromres.2018.07.008]

4 **Mulder R**, Croles FN, Mulder AB, Huntington JA, Meijer K, Lukens MV. SERPINC1 gene mutations in antithrombin deficiency. *Br J Haematol* 2017; **178**: 279-285 [PMID: 28317092 DOI: 10.1111/bjh.14658]

5 **Wypasek E**, Corral J, Alhenc-Gelas M, Sydor W, Iwaniec T, Celińska-Lowenhoff M, Potaczek DP, Blecharczyk A, Zawilska K, Musiał J, Undas A. Genetic characterization of antithrombin, protein C, and protein S deficiencies in Polish patients. *Pol Arch Intern Med* 2017; **127**: 512-523 [PMID: 28607330 DOI: 10.20452/pamw.4045]

6 **Perry DJ**, Carrell RW. Molecular genetics of human antithrombin deficiency. *Hum Mutat* 1996; **7**: 7-22 [PMID: 8664906 DOI: 10.1002/(SICI)1098-1004(1996)7:1<7::AID-HUMU2>3.0.CO;2-B]

7 **Navarro-Fernández J**, de la Morena-Barrio ME, Padilla J, Miñano A, Bohdan N, Águila S, Martínez-Martínez I, Sevivas TS, de Cos C, Fernández-Mosteirín N, Llamas P, Asenjo S, Medina P, Souto JC, Overvad K, Kristensen SR, Corral J, Vicente V. Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. *Thromb Haemost* 2016; **116**: 146-154 [PMID: 27098529 DOI: 10.1160/TH15-11-0871]

8 **Aiach M**, François D, Priollet P, Capron L, Roncato M, Alhenc-Gelas M, Fiessinger JN. An abnormal antithrombin III (AT III) with low heparin affinity: AT III Clichy. *Br J Haematol* 1987; **66**: 515-522 [PMID: 3663508 DOI: 10.1111/j.1365-2141.1987.tb01337.x]

9 **Picard V**, Bura A, Emmerich J, Alhenc-Gelas M, Biron C, Houbouyan-Reveillard LL, Molho P, Labatide-Alanore A, Sié P, Toulon P, Verdy E, Aiach M. Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene. *Br J Haematol* 2000; **110**: 731-734 [PMID: 10997988 DOI: 10.1046/j.1365-2141.2000.02245.x]

10 **Mitsuguro** M, Sakata T, Okamoto A, Kameda S, Kokubo Y, Tsutsumi Y, Sano M, Miyata T. Usefulness of antithrombin deficiency phenotypes for risk assessment of venous thromboembolism: type I deficiency as a strong risk factor for venous thromboembolism. *Int J Hematol* 2010; **92**: 468-473 [PMID: 20859710 DOI: 10.1007/s12185-010-0687-5]

11 **Alhenc-Gelas M**, Plu-Bureau G, Hugon-Rodin J, Picard V, Horellou MH; GFHT study group on Genetic Thrombophilia. Thrombotic risk according to SERPINC1 genotype in a large cohort of subjects with antithrombin inherited deficiency. *Thromb Haemost* 2017; **117**: 1040-1051 [PMID: 28300866 DOI: 10.1160/TH16-08-0635]

12 **Kearon C**, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. *Chest* 2016; **149**: 315-352 [PMID: 26867832 DOI: 10.1016/j.chest.2015.11.026]

13 **Witt DM**, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, Shehab N, Mock J, Myers T, Dentali F, Crowther MA, Agarwal A, Bhatt M, Khatib R, Riva JJ, Zhang Y, Guyatt G. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Adv* 2018; **2**: 3257-3291 [PMID: 30482765 DOI: 10.1182/bloodadvances.2018024893]

14 **Kawai H**, Matsushita H, Kawada H, Ogawa Y, Ando K. The Successful Prevention of Thromboembolism Using Rivaroxaban in a Patient with Antithrombin Deficiency during the Perioperative Period. *Intern Med* 2017; **56**: 2339-2342 [PMID: 28794370 DOI: 10.2169/internalmedicine.8487-16]

15 **Yamaguchi J**, Hara N, Yamaguchi T, Nagata Y, Nozato T, Miyamoto T. Successful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin III deficiency. *J Cardiol Cases* 2017; **16**: 144-147 [PMID: 30279820 DOI: 10.1016/j.jccase.2017.06.008]

16 **Minami K**, Kumagai K, Sugai Y, Nakamura K, Naito S, Oshima S. Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency. *Intern Med* 2018; **57**: 2025-2028 [PMID: 29526957 DOI: 10.2169/internalmedicine.0483-17]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** Dr. Sun reports grants from the National Natural Science Foundation of China, grants from Zhejiang Medical and Health Science and Technology Project, from the Natural Science Foundation of Zhejiang Province, during the conduct of the study.

**CARE Checklist (2016) statement:** The authors have read CARE Checklist (2016), and the manuscript was prepared and revised according to CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 27, 2023

**First decision:** May 8, 2023

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Barik R, India; Oley MH, Indonesia **S-Editor:** Li L **L-Editor:** A **P-Editor:**

**Figure Legends**

**图示

描述已自动生成**

图示

描述已自动生成

**Figure 1 Whole exome sequencing results.** A: The patient's parents did not previously have thrombosis and refused to undergo genetic sequencing; B: The mutation was found in *SERPINC1* (c.667T>C); C: The protein change resulted in Serine (S) changed to Proline (P) at position 223 (p.S223P).